

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-35 (Canceled)

--36. (New) A process of preparing (Gm-IV) from cow urine distillate, said process comprising:

a) mixing a volume of cow urine distillate with a volume of methanol, the volume of the methanol being half the volume of the cow urine distillate, and extracting with hexane;

b) lyophilizing a hexane fraction (Gm-I) and testing for similar activity as that of cow urine (*Go-mutra*);

c) extracting an aqueous fraction with ethyl acetate and lyophilizing an ethyl acetate fraction (Gm-II) and testing for similar activity as that of cow urine (*Go-mutra*);

d) extracting an aqueous fraction containing a white precipitate with butanol and lyophilizing a butanol fraction (Gm-III) containing a pale yellow precipitate and testing for similar activity as that of cow urine (*Go-mutra*); and

e) drying a remaining aqueous fraction containing a white crystalline precipitate (Gm-IV) and testing for similar activity as that of cow urine (*Go-mutra*).

37. (New) The process of Claim 36, wherein the lyophilized extract Gm-IV from the cow urine distillate is devoid of a cow urine smell.

38. (New) The process of Claim 36, wherein the lyophilized extract Gm-IV has the following physical characteristics: a white color, a solid crystalline form, water solubility, a melting point above 400°C, a specific gravity of 1.006 and an RF value in methanol:chloroform (50:50) phase: 0.65.

39. (New) The process of Claim 36, wherein the cow urine distillate has HPLC properties having two major peaks with retention times of 5.334 min and 11.310 min.

40. (New) A method of enhancing the activity of at least one of a nutraceutical, an antibiotic, an anti-infective and an anti-cancer agent, the method comprising combining cow urine distillate with at least one of a nutraceutical, an antibiotic, an anti-infective and an anti-cancer agent, wherein said cow urine distillate is present in an amount effective to enhance a nutraceutical effect, an antimicrobial effect, an anti-infective effect and an anti-cancer effect of the nutraceutical, the antibiotic, the anti-infective and the anti-cancer agent, respectively.

41. (New) The method of Claim 40, wherein the antibiotic is an antifungal agent.

42. (New) The method of Claim 40, wherein the antibiotic is a quinolone.

43. (New) The method of Claim 42, wherein the quinolone is a fluoroquinolone.

44. (New) The method of Claim 40, wherein the antibiotic is selected from the group consisting of nalidixic acid, rifampicin, tetracycline and ampicillin.

45. (New) The method of Claim 40, wherein the antibiotic is isoniazid in combination with hydrogen peroxide.

46. (New) The method of Claim 41, wherein the antifungal agent is selected from the group consisting of azoles, clotrimazole, mystatin and amphotericin.

47. (New) The method of Claim 40, wherein further comprising combining the cow urine distillate with at least one of the nutraceutical, the antibiotic, the anti-infective and the anti-cancer agent so that the cow urine distillate is present in a concentration of between .001 μ l/ml and 100 μ l/ml.

48. (New) The method of Claim 40, wherein the cow urine distillate is lyophilized.

51. (New) The method of Claim 50, wherein the anti-tuberculosis agent is selected from the group consisting of isoniazid, pyrazinamide and ethambutal.

52. (New) The method of Claim 40, wherein the anti-cancer agent is selected from the group consisting of Paclitaxol (Taxol).

53. (New) The method of Claim 40, further comprising combining the cow urine distillate with the anti-cancer agent in combination with anti-cancer molecules.

54. (New) A lyophilized bioactive product obtained from cow urine distillate having the following properties:

a white color, a solid crystalline form, water solubility, a melting point above 400°C, a specific gravity of 1.006 and an RF value in methanol: chloroform (50:50) phase 0.65.

55. (New) A pharmaceutical composition comprising an effective amount of at least one bioactive molecular species, and further comprising an amount of the lyophilized bioactive cow urine distillate product, as defined by Claim 54, to enhance/facilitate the activity and bioavailability of said at least one bioactive molecular species.

56. (New) A method for eliciting a bioactive response in an individual subject in need of such treatment, comprising administering thereto a pharmaceutical

composition comprising an effective amount of at least one bioactive molecular species, and further comprising an amount of cow urine distillate effective to enhance/facilitate the activity and bioavailability of the at least one bioactive molecular species.--